COMPLIANCE POLICY GUIDE (CPG)
CPG Sec. 325.100 Karaya Gum Powder and Related Devices for Use by Ostomates September 1987
- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Devices and Radiological HealthOffice of Regulatory Affairs
Karaya gum powder and devices made from karaya gum powder intended for use by ostomates have been the subject of recalls because the devices contained opportunistic pathogens.
Efforts to sterilize some of these devices by ethylene oxide and irradiation were unsuccessful. Ethylene oxide sterilization of karaya gum is generally not effective. Irradiation sterilization of consumer size containers of karaya gum powder is effective if the irradiation dose is intense. However, the performance of karaya gum powder and devices sterilized in this way is considered unsatisfactory as the irradiation destroys the qualities of the karaya gum and renders these products useless for their intended purpose.
In November 1976, information letters were sent to all known manufacturers of karaya gum devices, advising the firms that these devices should be labeled as nonsterile and that their use on reddened, abraded or excoriated skin is contraindicated. Sterile karaya gum powder was excluded from this labeling requirement. This policy was based on the fact that karaya gum is an essential accessory to ostomy appliances, and we are aware of no satisfactory substitutes available on the market.
Consequently by memorandum of May 5, 1977, the *Center for Devices and Radiological Health* requested the districts to send a followup letter to all firms who received the November 1976, information letter advising the firms of our new position as stated in the prior paragraph.
*The requirement that nonsterile karaya gum devices be labeled as nonsterile and that their use on reddened, abraded, and excoriated skin be contraindicated will not be mandatory, provided the devices meet the "Microbiological Attributes of Non-Sterile Pharmaceutical Products" as specified in the United States Pharmacopeia, XXI, page 1329*.
*Material between asterisks is new or revised*
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2020-D-0957.